Gene Solutions - Công ty cổ phần giải pháp Gene

Gene Solutions

Fund

Mekong Enterprise Fund IV

Deal Leader

Ashley Trang Pham

Website

Making genetic testing affordable and accessible for millions of Vietnamese

10 years of researching Cancer Biology and Genetics in the U.S was eye-opening for Dr. Nguyen Hoai Nghia when he discovered the benefits and applications of genetic testing. With the intention to make genetic testing affordable and accessible to millions of Vietnamese, thus transforming their health, he returned to Vietnam to start his entrepreneurial journey.

In 2017, Dr. Nghia together co-founded Gene Solutions with Dr. Nguyen Huu Nguyen (Deputy CEO), and Dr. Giang Hoa (R&D) with background and solid experience in genetics, cancer biology, clinical medicine, and biotechnology.

Nhà sáng lập công ty cổ phần giải pháp Gene (Gene Solutions)
Dr. Nguyen Hoai Nghia, Dr. Giang Hoa, and Dr. Nguyen Huu Nguyen.

Vietnam’s market-leading genetic testing business

Three years later, this innovative competitive advantage combined with an elite team with rich industry experience and leadership has enabled Gene Solutions to emerge as the leading genetic testing firm offering comprehensive solutions in reproductive health and clinical oncology, including early cancer detection and cancer recurrence monitoring.

By 2024, Gene Solutions is Asia’s DNA testing champion in both reproductive health and clinical oncology, recognized for its market leadership and remarkable achievements:

  • Over 2.2 million AI-enhanced NGS tests processed
  • 6 next-generation sequencing labs, including 2 CAP-accredited centers in Vietnam and Singapore
  • 50+ peer-reviewed publications, validating both scientific rigor and clinical relevance
  • A growing presence in 10+ Asian markets, driven by partnerships with leading hospital chains in Vietnam, the Philippines, Indonesia, and Thailand

For its flagship reproductive health tests, the company accounts for more than 80% market share, helping thousands of pregnant women access genetic technology at ease and at a more reasonable price.

In 1Q23, Gene Solutions launched the most affordable Non-Invasive Prenatal Testing (“NIPT”) product in Vietnam, triSureFirst, which is a blood test for pregnant women to screen the 3 most common abnormalities for the fetus: Down, Edwards, and Patau syndromes.

They also work with 2,000+ oncology hospitals, prestigious clinics, and 2,500+ partner doctors across Vietnam to provide holistic care before, during, and after the tests.

Dịch vụ Xét Nghiệm triSure Procare nipt của Gene Solutions - viện di truyền y học

Revolution in cancer screening and detection

Phòng thí nghiệm của công ty cổ phần giải pháp Gene - Gene Solutions Vietnam

In 2023, with the outstanding advantage of the advanced machine learning system and large genetic data, Gene Solution has invented a SPOT-MAS™ liquid biopsy technology to enhance the early-stage detection of many cancers as the next breakthrough pillar.

SPOT-MAS™ accurately detects abnormal genomic factors of multiple common types of cancer including liver cancer, lung cancer, breast cancer and colorectal cancer, stomach cancer.

With a higher performance rate of detecting rare circulating tumor DNA (ctDNA) and lower costs compared to market standards, SPOT-MAS™ initiates affordable liquid-biopsy Point-Of-Care (POC) for cancer management in developing countries where 75% of global cancer deaths, proved by researchers.

Also in 2023, Gene Solutions launched K-TRACK™ — a ctDNA-based tool to monitor cancer recurrence. It detects Minimal Residual Disease and provides critical insights for a patient’s comprehensive genomic profile, allowing precise identification of treatment eligibility — predicting disease-free survival and early relapse detection in cancer patients.
Once a personalized genetic profile is established, Gene Solutions tracks ctDNA-MRD based on each patient’s profile. K-TRACK™ has been validated in scientific journals for high sensitivity and specificity. It can predict recurrence up to 19 months earlier than traditional imaging methods.

Red Wok

Red Wok

Next Investment